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Aggregation of a-synuclein and formation of inclu-
sions are hallmarks of Parkinson’s disease (PD).
Aggregate formation is affected by cellular environ-
ment, but it has been studied almost exclusively in
cell-free systems. We quantitatively analyzed a-synu-
clein inclusion formation and clearance in a yeast cell
model of PD expressing either wild-type (WT) a-synu-
clein or the disease-associated A53Tmutant from the
galactose (Gal)-inducible promoter. A computer-
controlled microfluidics device regulated a-synuclein
in cells by means of closed-loop feedback control.
We demonstrated that inclusion formation is strictly
concentration dependent and that the aggregation
threshold of the A53T mutant is about half of the WT
a-synuclein (56%). We chemically modulated the
proteasomal and autophagic pathways and demon-
strated that autophagy is the main determinant of
A53T a-synuclein inclusions’ clearance. In addition
to proposing a technology to overcome current limita-
tions in dynamically regulating protein expression
levels, our results contribute to the biology of PD
and have relevance for therapeutic applications.
INTRODUCTION
a-Synuclein, encoded by the SNCA gene, is a small (14.5 kDa),
intrinsically disordered protein expressed abundantly in a
healthy brain. The precise physiological functions of a-synuclein
remain poorly understood (Fusco et al., 2016), although recent
findings point to a role in vesicle trafficking and synaptic physi-
ology (Wislet-Gendebien et al., 2006; Auluck et al., 2010). In
the human brain, an abnormal increase of a-synuclein expres-
sion levels may result in the aggregation of the protein into large
complexes and amyloidogenic fibrils with the formation of intra-
neuronal proteinaceous inclusions known as Lewy bodies
(Goedert et al., 2013), linked to the Parkinson’s disease (PD)
pathogenesis (Goedert et al., 2017). Although the matter is still
the subject of debate, it is thought that inclusions in the cell
are generated by the impairment of degradative pathways and916 Cell Reports 27, 916–927, April 16, 2019 ª 2019 The Author(s).
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2016). The mechanisms underlying the formation of protein ag-
gregates seem to be concentration dependent (Singleton et al.,
2003). Indeed, either duplication or triplication of the wild-type
(WT) a-synuclein gene locus is sufficient to cause familial PD
(Singleton et al., 2003; Farrer et al., 2004; Iba´n˜ez et al., 2004).
Moreover, missense mutations in the SNCA gene cause early-
onset (A53T, E64K, A30P, G51D, and A53E) and late-onset
(H50Q) forms of PD (Polymeropoulos et al., 1997; Kr€uger et al.,
1998; Zarranz et al., 2004; Appel-Cresswell et al., 2013; Prouka-
kis et al., 2013; Kiely et al., 2013; Pasanen et al., 2014; Martikai-
nen et al., 2015).
Cell-free, cellular, and animal models of PD have been
developed to study the formation of inclusions (Visanji et al.,
2016; Koprich et al., 2017; La´zaro et al., 2017). Pioneering
studies have dissected aggregate and fibril formation in cell-
free systems using purified a-synuclein protein (Giasson
et al., 1999; Conway et al., 1998). These earlier in vitro studies
were semiquantitative in that they did not quantify threshold
concentrations for aggregation nor the difference between
WT and mutant a-synuclein proteins. Subsequent in vitro
studies, building on these previous works, have now precisely
quantified the molecular steps of a-synuclein fibril formation
and rate constants of associated reactions, thus greatly
contributing to current understanding of a-synuclein pathobi-
ology (Giehm et al., 2011; Cohen et al., 2011, 2012; Buell
et al., 2014; Garcia et al., 2014; Lorenzen et al., 2014;
Galvagnion et al., 2015, 2016; Flagmeier et al., 2016; Iljina
et al., 2016). These in vitro studies have also shown that
a-synuclein aggregation kinetics are strongly affected by the
presence of lipid vesicles, thus highlighting the importance
of studying such processes in whole cells, because the
cellular environment is much more complex than the
commonly used in vitro conditions (Flagmeier et al., 2016; Gal-
vagnion et al., 2015).
Biological processes involved in a-synuclein inclusion forma-
tion and clearance are well conserved across evolution, hence
yeast can be used to elucidate the molecular basis of the human
disease and to screen for therapeutic drugs (Menezes et al.,
2015; Schneider et al., 2018). Since its inception (Outeiro and
Lindquist, 2003), the yeast PD model with heterologous expres-
sion of a-synuclein has been successfully used not only to study
molecular mechanisms of the PD but also for high-throughputcommons.org/licenses/by/4.0/).
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Figure 1. Construction and Characteriza-
tion of Yeast Strains Expressing Wild-
Type or Mutant (A53T) Human a-Synuclein
from the Galactose-Inducible Promoter
(A) Schematic of the constructs to express either
the human a-synuclein gene (SNCA) or the dis-
ease-associated A53T mutant in yeast. a-Synu-
clein is fused to a GFP reporter under the control
of the galactose-inducible promoter PGAL1. In
each strain (WT or A53T), two copies of the
construct were genomically integrated and at
least one copy was expressed from a yeast
centromeric plasmid (YCp) (STAR Methods). A
red fluorescent reporter (mCherry protein) under
the control of the constitutive promoter PTEF2was
also integrated in both yeast strains.
(B) Ten-fold serial dilutions of yeast strains ex-
pressing either WT and A53T in log-phase cultures
were spotted on synthetic complete drop-out me-
dia supplemented with either glucose (uninduced)
or galactose (induced) to assess cell viability upon
a-synuclein induction (STAR Methods).
(C) Schematic illustration of the integrated experi-
mental platform for automated microfluidics feed-
back control of a-synuclein in yeast cells.drug and genetic screenings (Zabrocki et al., 2008; Menezes
et al., 2015; Chen et al., 2017). In this model, a-synuclein is
expressed from the galactose-inducible promoter, and protein
inclusions form with ensuing growth defects and cell death
(Outeiro and Lindquist, 2003; Cooper et al., 2006; Petroi et al.,
2012).
The main limitation of the yeast PD model is that despite
forming a-synuclein cytoplasmic inclusions (Outeiro and Lind-
quist, 2003; Cooper et al., 2006), which are also found in hu-
man neurons (Giasson et al., 1999; Cooper et al., 2006), these
are not comprised of insoluble a-synuclein amyloid fibrils as
found in Lewy bodies (Soper et al., 2008). Rather, inclusions
in yeast consist of clusters of vesicles that contain a-synuclein
monomers, as well as a-synuclein aggregates formed by large
oligomeric species (Soper et al., 2008; Sancenon et al., 2012;
Tenreiro et al., 2014; Menezes et al., 2015). Interestingly, sol-
uble oligomers of a-synuclein are also enriched in PD patients,
and they likely represent an early aggregated form of the pro-
tein that over time transitions to much larger, insoluble aggre-
gates and amyloid fibrils (Sharon et al., 2003).
Because a-synuclein controls vesicular dynamics and recy-
cling in neurons, its basic functions seem to be maintained
when the protein is expressed in yeast, thus making yeast a rele-
vant model to study the biology and pathobiology of a-synuclein
(Zabrocki et al., 2008).
So far, the process ofa-synuclein aggregation and inclusion for-
mation in vivo in the yeast PD model has been characterized only
qualitatively in terms of the number of integrated genome copies
because of technological limitations (Menezes et al., 2015;Outeiro
and Lindquist, 2003; Popova et al., 2015). Hence, the most in-Cedepth characterization currently available
is that three copies of WT a-synuclein,
versus two copies of A53T a-synuclein,are needed to observe a-synuclein inclusions in the yeast PD
model (Petroi et al., 2012).
Here, we overcame current technical limitations enabling
characterization of the yeast PD model quantitatively by dynam-
ically regulating a-synuclein protein expression over time in the
very same cell population, that is, without the need of using
strains with different numbers of genomic integrations of a-syn-
uclein. In so doing, we demonstrated that a-synuclein inclusion
formation in yeast is strictly concentration dependent, but
not time dependent. We precisely measured both the WT and
disease-associated A53T a-synuclein protein aggregation
thresholds, we studied the effects of inclusions on cell-cycle
progression, and we dissected the contributions of proteasomal
and autophagic pathways on the dynamics of A53T a-synuclein
inclusions’ clearance.
In addition to contributing to the biology of PD, our results have
relevance for therapeutic applications because the yeast PD
model is extensively used in large-scale screening of therapeutic
small molecules and modifier genes (Cooper et al., 2006; Chen
et al., 2017).
RESULTS
Construction and Characterization of Yeast Strains
Expressing WT or Mutant (A53T) Human a-Synuclein
from the Galactose-Inducible Promoter
We generated two S. cerevisiae strains expressing multiple in-
tegrated copies of either human WT a-synuclein or the mutant
A53T a-synuclein fused to the GFP under the control of the
GAL-inducible promoter PGAL1 (Figure 1A). Two copies werell Reports 27, 916–927, April 16, 2019 917
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Figure 2. Automated Microfluidics Feed-
back Control Enables Precise Regulation of
a-Synuclein Expression over Time in Both
WT a-Synuclein Strain and A53T Mutant
Strain
a-Synuclein-GFP fluorescence was quantified in
each cell and normalized to the red fluorescence
(mCherry protein) with a custom-made image pro-
cessing algorithm (STARMethods). Light gray lines
show representative examples of single-cell traces
(STAR Methods). Single-cell traces may start or
end at different times, because of cells being born
and cells being pushed out of the field of view.
(A and B) Population-averaged a-synuclein-GFP
fluorescence (blue with SD across cells in gray) for
the WT a-synuclein strain (A) and the A53T mutant
a-synuclein strain (B) grown in the microfluidics
device in the presence of galactose. Examples of
images beloweach timecourse showWTandA53T
mutant a-synuclein-GFP at the indicated time
points.
(C and D) Population-averaged a-synuclein-GFP
fluorescence (blue with SD in gray) was controlled
to the reference target value (yellow) by automati-
cally switching between glucose and galactose
(brown) as computed in real time by the Model
Predictive Control strategy (STAR Methods). No
a-synuclein inclusions were observed over the
course of the experiment in both strains. Examples
of images below each timecourse show (C)WTand
(D) A53T mutant a-synuclein-GFP at the indicated
time points.
See also Figure S1.integrated in specific loci on the chromosomes, and at least
one copy was expressed from a yeast centromeric plasmid
(YCp) (STAR Methods). In addition, a genomically integrated
red fluorescent reporter (mCherry) was constitutively ex-
pressed from the PTEF2 promoter (Figure 1A). mCherry protein
fluorescence was used to normalize a-synuclein-GFP fluores-
cence across different experiments and strains (STAR
Methods). As shown in Figure 1B, induction of a-synuclein
by galactose treatment resulted in a reduced growth rate in
both strains, likely caused by toxicity of protein aggregates,
as previously reported (Outeiro and Lindquist, 2003; Cooper
et al., 2006). Time-lapse microfluidics experiments confirmed
the formation of cytoplasmic inclusions when a-synuclein was
overexpressed (Figures 2A and 2B). The observed cell-to-cell
variability in fluorescence levels (shadowed area in Figures 2A
and 2B) is well documented and extensively studied in yeast,
and is mainly caused by extrinsic noise, that is, global differ-
ences in cellular environment, including growth rate and the
concentration of RNA polymerases and ribosomes (Elowitz
et al., 2002; Raser and O’Shea, 2004; Rosenfeld et al.,
2005; Pedraza and van Oudenaarden, 2005). We quantified
cell-to-cell variability as the SD of fluorescence across cells
divided by their mean for each time point (also known as
coefficient of variation [CV]) as reported in Figure S1. The
value of the CV is well in line with those previously observed
in yeast (Volfson et al., 2006).918 Cell Reports 27, 916–927, April 16, 2019Automatic Feedback Control of a-Synuclein Expression
To quantitatively study WT and mutant a-synuclein aggregation
in the two strains, wemade use of automatedmicrofluidics feed-
back control of gene expression (Fiore et al., 2016; Menolascina
et al., 2014) to precisely regulate the amount of a-synuclein
produced by the cells over time, as shown in Figure 1C (STAR
Methods). In brief, this automated platform performs the
following steps: (1) a-synuclein-GFP expression is measured in
yeast cells with a time-lapse fluorescence microscope at 5-min
sampling intervals, (2) a-synuclein protein level is quantified in
individual cells from fluorescent images with a custom image
processing algorithm, (3) a computer implementing a controller
computes the duration of the galactose pulse (ranging from
0 to 5 min) needed to minimize the difference between the target
a-synuclein level and the actual population-averaged fluores-
cence intensity across the cells, and (4) an automated set of
syringes delivers galactose (or glucose) to the cell chamber in
the microfluidic device. The controller implements a model pre-
dictive control (MPC) strategy to guarantee the tracking of the
target reference a-synuclein concentrations at the cell popula-
tion level (Perrino et al., 2016) (STAR Methods). We first applied
this control strategy to regulate a-synuclein expression at a
sub-aggregation level (four normalized fluorescence units) for
2,000 min in both the WT strain (Figure 2C) and the A53T mutant
strain (Figure 2D). Both time-lapse feedback control experiments
did not show any protein aggregates in the cell population, unlike
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Figure 3. Automated Microfluidics Feedback Control of a-Synuclein Expression at Nine Increasing Levels to Observe and Quantify
a-Synuclein Aggregation Thresholds in Both WT a-Synuclein Strain and A53T Mutant Strain
(A–F) Six control experiments were performed to increase a-synuclein protein expression stepwise in both the WT a-synuclein strain (A–C) and mutant A53T
a-synuclein strain (D–F). Population-averaged a-synuclein expression (blue with SD in gray) was tightly regulated to the target expression levels (yellow) by
automatically switching between galactose and glucose (brown) as directed by the controller (STAR Methods). a-Synuclein-GFP fluorescence in single cells is
normalized to mCherry fluorescence within each cell (STAR Methods) to enable comparison across cells, strains, and experiments. Examples of images below
each time course showWT and A53Tmutant a-synuclein-GFP at the indicated time points (A–F). Prior to the formation of inclusions, a-synuclein-GFP ismainly on
the membrane, whereas inclusions appear as bright cytoplasmic spots.
See also Videos S1 and S2.cells continuously grown in galactose (Figures 2A and 2B), thus
demonstrating the ability of the platform to control a-synuclein
expression in the cell population.
Inclusion Formation in Both WT and Mutant a-Synuclein
Strains Is Strictly Concentration Dependent
We regulated a-synuclein expression to nine increasing levels in
both WT and A53T mutant strains in a stepwise fashion, as
shown in Figure 3. Each level was maintained for 500 min.
At low expression levels (a-synuclein-GFP fluorescence % 4
normalized units), both WT and A53T mutant a-synuclein pro-
teins were localized to the cell membrane (Figures 3A and 3D).
At higher concentrations, WT and A53T a-synuclein proteins
began aggregating in some cells, with inclusions first appearing
close to the plasma membrane (Figures 3C and 3F; Videos S1
and S2), in agreement with previous observations (Lee et al.,
2002; Galvagnion et al., 2015; Popova et al., 2015).To test whether there is a precise concentration threshold
above which a-synuclein inclusions occur, we selected single-
cell time course profiles with a minimum duration of 500 min
from the time-lapse control experiments in Figure 3 (STAR
Methods). We thus obtained two single-cell datasets: one for
the WT a-synuclein strain and the other for the A53T mutant
a-synuclein strain. For each cell, we quantified the normalized
fluorescence of a-synuclein upon inclusion formation (red dots,
Figures 4A and 4B). As shown in Figure 4C, the distributions of
fluorescence in the WT strain are significantly higher than in
the A53T a-synuclein strain (Student’s t test, p = 1.06 3 1023).
In order to precisely quantify WT and A53T a-synuclein aggrega-
tion thresholds, we trained a classifier that, based solely on the
measured fluorescence, assigned to each single-cell image
(i.e., for each cell at each time point) a label indicating the pres-
ence or absence of inclusions in the image. When the fluores-
cence level is above a selected threshold, the classifier assignsCell Reports 27, 916–927, April 16, 2019 919
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Figure 4. Single-Cell Time Course of a-Synuclein Expression Reveals Specific Aggregation Thresholds for Both the Wild-Type and Disease-
Associated Mutant Forms
a-Synuclein-GFP fluorescence was quantified in each cell and normalized to the red fluorescence (mCherry protein) with a custom-made image processing
algorithm (STAR Methods). ***p < 0.001, ****p < 0.0001, Student’s t test.
(A and B) Heatmap representation of single-cell a-synuclein-GFP fluorescence for theWT strain (A) and A53T strain (B) during the control experiments reported in
Figure 3, where a-synuclein-GFP increases in a stepwise fashion. Each row represents a single cell and each column a 5-min time interval. Single-cell time-lapse
imaging was used to detect the aggregation time point (red dot in each row), defined as the moment at which a-synuclein inclusions become visible at the cell
membrane. Only cells that formed inclusions are shown. Some cells did not show any inclusions during their lifespan because they did not reach the aggregation
threshold. Of the cells that reach the aggregation threshold, the majority (83% for WT and 86% for A53T) exhibited inclusions. Single-cell traces may start or end
at different times, because of cells being born and cells being pushed out of the field of view.
(C) Distribution of the a-synuclein fluorescence at the aggregation time point across single cells in the WT (n = 53) and A53T (n = 64) a-synuclein strains. The
aggregation threshold of the WT strain is significantly higher than the A53T strain (Student’s t test, p = 1.06 3 1023).
(D) Distribution of the a-synuclein aggregation delay across single cells in the WT (n = 53) and A53T (n = 64) a-synuclein strains. Aggregation delay is
defined as the time interval prior to the aggregation time point during which the a-synuclein-GFP fluorescence level was within 1 normalized unit from the
(legend continued on next page)
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the ‘‘aggregation’’ label, whereas when the fluorescence level is
below the threshold, it assigns the ‘‘no aggregation’’ label. The
performance of the classifier was evaluated according to its ac-
curacy, ACC, defined as the rate of true predictions (STAR
Methods). The fluorescence threshold that gives the most accu-
rate prediction is of 13.1 normalized units for WT a-synuclein
(ACC = 83.26%) and 7.4 normalized units for A53T a-synuclein
(ACC = 85.97%). These results show that the A53T mutation
causes the aggregation threshold to become about half of the
WT a-synuclein threshold (56%) (STAR Methods).
Next, we asked how variable this threshold is across individual
cells. To this end, we computed the CV of the fluorescence of in-
dividual cells at the time of aggregation. We found that the CV is
quite small for both WT and A53T mutant a-synuclein strains
(CVWT = 0.18;CVA53T = 0.28), and that the variability in the aggre-
gation threshold is slightly increased by the mutation.
Finally, we estimated the aggregation delay as the time
needed for inclusion formation once a-synuclein-GFP fluores-
cence level in the cell has reached the aggregation threshold.
We found that inclusions form within 12 min after reaching the
aggregation threshold in the WT strain and within 20 min in
the A53T strain (Figure 4D; STARMethods). Despite these values
being statistically different (Figure 4D), they differ by only 8 min,
hence this difference may be negligible in biological terms,
suggesting that the A53T mutation does not affect inclusion
formation dynamics in vivo. It could also be possible that this
difference is caused by the higher concentration of the WT
a-synuclein needed for inclusion formation with respect to the
mutant form (Figure 4C), resulting in faster protein aggregation
(Galvagnion et al., 2015).
Our results support the conclusion that a-synuclein aggrega-
tion and inclusion formation in live yeast cells strictly follow a
phase transition-like phenomenon governed by a threshold ef-
fect, such that inclusions will form only in cells expressing the
protein above the threshold. Previous studies have suggested
that yeast cells stop dividing upon a-synuclein aggregation.
We therefore analyzed single-cell traces to quantify cell-cycle
duration before and after aggregation. We estimated an increase
in cell-cycle duration for both theWT a-synuclein strain (from 110
to 145 min; Figure 4E; Student’s t test, p = 7.29 3 107) and the
A53Tmutant strain (96 to 140min, Figure 4E; Student’s t test, p =
1.413 1017). Interestingly, we observed only a few instances of
cells that completely stopped dividing upon aggregation (6% for
the WT a-synuclein strain and 11% for the A53T a-synuclein
mutant strain). These results show that a-synuclein toxicity in
our settingmainly manifests in a slowdown of cell-cycle progres-
sion, which is similar between the WT and A53T mutant strains.
Single-Cell Feedback Control of A53T Mutant
a-Synuclein to Study Inclusion Formation andClearance
Experiments performed so far were aimed at controlling the
average expression of a-synuclein across the cell population.aggregation threshold. The average aggregation delay of the A53T mutant
p = 0.0003).
(E) Distributions of the cell-cycle duration across single cells before and after fo
a-synuclein strains. The cell-cycle duration after a-synuclein inclusions appear in
(Student’s t test, p = 1.41 3 1017) strains. Outliers were removed according toWe next regulated a-synuclein expression at the single-cell level
in order to observe inclusion formation and clearance in the
same cell. We first performed a time-lapse control experiment
to regulate A53T a-synuclein expression at two different levels:
500 min at 6 normalized units (below the A53T mutant aggrega-
tion threshold of 7.4) and 500 min at 10 normalized units (above
the aggregation threshold) (Figures 5A and 5B; Video S3). At the
beginning of the control experiment, we randomly selected one
cell to be controlled. Single-cell a-synuclein concentration was
maintained close to the reference target levels by the automated
microfluidics control platform, as shown in Figures 5A and 5B
(STAR Methods). As expected, no inclusions were present
when the expression level was kept close to but under the
threshold level (Figure 5B). Inclusions instead became apparent
when the level was increased to 10 normalized units (n.u.) (Fig-
ure 5B). Concomitantly, we observed an increase in cell-cycle
duration (Figure 5A; Video S3) in agreement with the results ob-
tained when controlling the whole population (Figure 4E). We
then performed another single-cell control experiment (Fig-
ure 5C; Video S4), this time regulating A53T a-synuclein expres-
sion at three different levels: 500 min at 6 n.u., 500 min at 10 n.u.,
and 500 min at 14 n.u. Single-cell time-lapse imaging confirmed
that a-synuclein did not form inclusions when expressed below
the threshold (Figure 5D) and that the cell was dividing normally
(Figure 5C; Video S4). As expected, inclusions appeared soon
after the threshold was reached, together with an increase in
cell-cycle duration (Figure 5C; Video S4). Interestingly, during
the first 1,200 min in Figure 5C, before the cell cycle starts to
slow down, a small drop in fluorescence (on average 2.86%)
can be observed after each cell division. Because the Gal
promoter driving a-synuclein transcription is not cell cycle
dependent and because proteins are constantly produced in
yeast during the cell cycle (Polymenis and Aramayo, 2015), this
small drop may be the result of an a-synuclein-GFP dilution
caused by volume growth during the cell cycle.
To investigate the dynamics of inclusion clearance, we
repressed A53T a-synuclein expression at time 1,500 min by
providing glucose to the cell for an additional 500min (Figure 5C).
Interestingly, fluorescence intensity remained constant for
130 min from the removal of galactose (black dashed line in Fig-
ure 5C); afterward the cell cycle restarted and its duration re-
turned close to pre-aggregation values despite inclusions still
being present. Inclusions disappeared completely 495 min
following galactose removal (Figure 5D; Video S4).
Quantification of Autophagic and Proteasomal
Contributions to the Clearance of Mutant A53T
a-Synuclein
To further investigate the dynamics of A53T a-synuclein inclu-
sions’ clearance and to dissect the relative contributions of pro-
teasomal and autophagic pathways, we performed a series of
time-lapse microfluidics experiments chemically modulatingstrain is only a few minutes higher than the WT strain (Student’s t test,
rmation of a-synuclein inclusions in both the WT (n = 53) and A53T (n = 64)
creases significantly in both WT (Student’s t test, p = 7.29 3 107) and A53T
the boxplot rule.
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Figure 5. Single-Cell Automated Microfluidics Feedback Control Enables Real-Time Monitoring of Mutant A53T a-Synuclein Aggregation
and Clearance Dynamics
(A–D) Two single-cell control experiments are shown. a-Synuclein-GFP expression was quantified with an image processing algorithm (STAR Methods) and
normalized to the red fluorescent reporter (mCherry protein; STAR Methods). Cells were tracked in real-time using a custom algorithm (STAR Methods). The
budded phase of the cell cycle indicated by shaded gray areas was identified using a custom procedure (STAR Methods). Bud formation (dashed blue line) and
cell division (dotted blue line) are also shown. Red circles indicate a-synuclein-GFP fluorescence at cell divisions.
(A) Automatic feedback control of A53T a-synuclein-GFP expression (blue) in a single cell at two different levels (6 and 10 in yellow) below and above the A53T
aggregation threshold (7.4 in red).
(B) Single-cell fluorescence images of the a-synuclein-GFP time course in (A). Images are taken at 5-min intervals. Red squares highlight images where
a-synuclein-GFP fluorescence level is at or above the aggregation threshold. a-Synuclein-GFP inclusions appear only once the aggregation threshold is reached.
(C) Automatic feedback control of A53T a-synuclein-GFP expression (blue) in a single cell at three different levels (6, 10, and 14 in yellow) below and above the
A53T aggregation threshold (7.4 in red). To investigate clearance of a-synuclein inclusions, at the end of the control experiment (1,500min), glucose was provided
to the cells, thus inhibiting A53T a-synuclein-GFP expression.
(D) Single-cell fluorescence images of the a-synuclein-GFP time course in (C). Red squares highlight images where a-synuclein-GFP fluorescence level is at
or above the aggregation threshold. a-Synuclein-GFP inclusions appear once the aggregation threshold is reached. Upon glucose treatment (1,500 min),
a-synuclein-GFP expression decreases (from 1,500 to 2,000 min), and inclusions are cleared.
See also Videos S3 and S4.the proteasomal and autophagic pathways. Indeed, a-synuclein
protein can be degraded both by the proteasome and by auto-
phagy (Webb et al., 2003), but the latter has been proposed to
be the main driver in clearing WT a-synuclein inclusions in the
yeast PD model (Petroi et al., 2012; Popova et al., 2015). Here,
we tested the effects of: (1) rapamycin, an autophagy inducer
(Kamada et al., 2004); (2) PMSF, an autophagy inhibitor (Take-
shige et al., 1992); and (3) MG132, a proteasome inhibitor (Lee
and Goldberg, 1998). In order for these compounds to accumu-
late within yeast cells, we modified the mutant A53T strain by
deleting the Pleiotropic Drug Resistance gene PDR5 encoding
an efflux transporter (Ernst et al., 2005).
We analyzed A53T a-synuclein inclusions’ clearance both at
the population and single-cell level in the mutant Dpdr5 A53T
strain upon treatment with the three compounds, as shown in
Figure 6. We grew cells overnight in the presence of galactose
in the microfluidics device to induce formation of a-synuclein in-
clusions; at time 0 min, galactose was replaced by glucose and
fluorescence was quantified in individual cells (STAR Methods).
Figure 6A reports the population-averaged fluorescence
computed from single-cell traces across the indicated condi-922 Cell Reports 27, 916–927, April 16, 2019tions. Enhancement of autophagy by rapamycin (yellow line) ac-
celerates clearance compared with untreated control (red line),
whereas inhibition of autophagy by PMSF slows it down (dark
blue line). The proteasome inhibitor MG132 also slowed clear-
ance dynamics, but to a lesser extent than PMSF (light blue
line). These results clearly support the role of autophagy as ama-
jor player in the clearance of A53T a-synuclein inclusions.
At the population level, however, it is not possible to assess
what are the main determinants of the observed differences in
A53T a-synuclein inclusions’ clearance dynamics. We thus
analyzed single-cell traces upon the different treatment condi-
tions (Figures 6B–6E). For each cell, we measured four parame-
ters as depicted in Figure 6B: (1) the time to first bud (TFB),
defined as the time elapsed between the beginning of the exper-
iment and the formation of the first cell bud; (2) the mean fluores-
cence value during the TFB; (3) the duration of each cell cycle;
and (4) the drop at division after each cell cycle, defined as the
percentage decrease in fluorescence between two consecutive
cell cycles. Figure 6F shows the distribution of the TFB for all
the cells and across treatments. Rapamycin significantly
reduced the TFB compared with untreated cells, whereas
A F
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Figure 6. Quantification of Autophagic and
Proteasomal Contributions to the Clear-
ance of Mutant A53T a-Synuclein
We tested the effects of three compounds: (1)
rapamycin (100 nM), an autophagy inducer; (2)
PMSF (1 mM), an autophagy inhibitor; and (3)
MG132 (50 mM), a proteasome inhibitor, in the
mutant A53T a-synuclein strain deleted for the
Pleiotropic Drug Resistance gene PDR5 encod-
ing an efflux transporter to enable accumulation
of the small molecules (STAR Methods). Cells
were grown overnight in the presence of galac-
tose to induce formation of a-synuclein in-
clusions. At time 0 min, galactose was replaced
by glucose, and a-synuclein-GFP fluorescence
was quantified in individual cells in the micro-
fluidics device using a custom-made image pro-
cessing algorithm (STAR Methods). Only cells
that were present from the beginning to the end of
the experiment were considered.
(A) Population-averaged a-synuclein-GFP fluo-
rescence computed from single-cell traces
(STAR Methods) in each of the four conditions
tested. t1/2 is time necessary for a-synuclein-GFP
fluorescence to become half of its initial value.
(B–E) Representative single-cell time course
(solid blue lines) in the Dpdr5 A53T a-synuclein
yeast strain for each of the indicated conditions:
untreated (B), rapamycin (C), MG132 (D), and
PMSF (E). a-Synuclein-GFP fluorescence in each
individual cell is normalized to the mean fluores-
cence during the calibration phase (STAR
Methods). The time at which a-synuclein in-
clusions disappear is indicated by a yellow line
(STAR Methods). The budded phase of the cell
cycle is indicated by shaded gray areas. Bud
formation (dashed blue line) and cell division
(dotted blue line) are also shown. We defined four
parameters as indicated in (B): time to first bud is
defined as the time elapsed between the begin-
ning of the experiment and the formation of the
first bud of the cell. The mean fluorescence (solid
black lines) is defined as the average fluores-
cence from the beginning of the experiment until
the time to first bud. The drop of fluorescence at
division is defined as the percentage decrease in
fluorescence during the budded phase. The cell-
cycle duration is defined as the time between two consecutive budding events. Experimental fluorescence at division (red circles) and model-predicted fluo-
rescence, assuming a drop in fluorescence of 38% at division (Jonas et al., 2018) caused by dilution (red squares), are also shown.
(F–I) Distribution of time to first bud (F), mean fluorescence (G), duration of cell cycle (H), and drop at division (I) across single cells in the different conditions:
untreated (n = 25), rapamycin (n = 14), MG132 (n = 24), and PMSF (n = 48). Solid black lines are the medians in each condition. Horizontal square brackets
represent statistically significant pairwise comparisons with median values between conditions changing by at least 10%. Dashed horizontal square brackets
represent pairwise comparison with median values between conditions changing less than 10%. *p % 0.1, **p % 0.05; Conover-Iman test of multiple com-
parisons using rank sums. The number of points in (H) and (I) is higher because each cell undergoesmultiple divisions during the experiment; each point refers to a
cell cycle in untreated (n = 91), rapamycin (n = 73), MG132 (n = 49), and PMSF (n = 137) condition.
n.s., not significant. See also Figures S2 and S3 and Video S5.PMSF increased it, as did MG132 albeit to a lesser extent (Fig-
ure 6F). Interestingly, the mean fluorescence value during the
TFB was not significantly affected by treatments and remained
close to 1, which is the value of fluorescence at the beginning
of the experiment (Figure 6G). Cell-cycle duration, in Figure 6H,
was significantly increased byMG132 treatment only. This effect
of MG132 has been previously reported; indeed, these cells
exhibit morphological defects forming pseudohyphae, whichare probably caused by impairment of cell-cycle proteins’ degra-
dation (Collins et al., 2010). The drop in fluorescence between
consecutive cell cycles is reported in Figure 6I and was not
significantly affected by any treatment, and on average it is
less than 50% independently of the treatment. This is in agree-
ment with a dilution mechanism caused by yeast asymmetric
cell division, where the mother cell is reported to shed on
average 38% of its total mass to the daughter cell (Jonas et al.,Cell Reports 27, 916–927, April 16, 2019 923
2018). Indeed, a simple mathematical model that assumes a
drop of 38% in fluorescence at each cell cycle recapitulates
the decrease in fluorescence over time in each of the cells inde-
pendently of the treatment (red squares in Figures 6B–6E; Fig-
ure S3) (STAR Methods).
This quantitative analysis shows that the clearance dynamics
of a-synuclein inclusions observed at the population level (Fig-
ure 6A) largely result from the time it takes for each cell to bud
following inhibition of a-synuclein expression by glucose, i.e.,
the TFB in Figure 6F. Interestingly, during this time no measur-
able decrease in fluorescence can be observed (Figure 6G),
whereas inclusions are still present (Figures 6B–6D; Video S5).
It has been reported that GFP is relatively stable in the vacuole,
hence it may be possible that only the a-synuclein moiety of the
a-synuclein-GFP fusion protein is being degraded during this
time (Delorme-Axford et al., 2015). We also computed the time
it takes for a-synuclein inclusions to disappear in each single
cell across the different conditions and found it to be highly
correlated with the TFB (Pearson’s product moment correlation
coefficient r = 0.77; p < 2.2 3 1016; Figure S2B). This result
shows that the TFB can be used as a proxy to predict when in-
clusions will disappear.
Finally, we checked whether impairment of either proteasomal
or autophagic pathways affects a-synuclein protein clearance
when this is expressed below its aggregation threshold and
thus when no inclusions are present.We performedmicrofluidics
control experiments in the mutant Dpdr5 A53T strain to reach
and maintain an a-synuclein expression level of 4 normalized
units for 500 min, which is below the aggregation threshold of
mutant A53T synuclein, followed by inhibition of a-synuclein
expression for an additional 500 min, as shown in Figure S3. At
the population level, treatment with either rapamycin or PMSF
had no measurable effects on clearance dynamics (Figure S3),
demonstrating that autophagy has no role in A53T a-synuclein
protein clearance when inclusions are not present. Cells treated
with MG132 showed a marginal impairment of the clearance dy-
namics (Figure S3), which is likely driven by MG132 effects on
the cell cycle and hence dilution, rather than to a direct effect
of proteasome inhibition on a-synuclein. Indeed, because inclu-
sions are not present, yeast cells continuously proliferate and
hence dilution caused by cell division is the main driver of the
fluorescence decay in these experiments.
DISCUSSION
In this work, we applied an innovative technological platform to
quantitatively study the effect of a-synuclein dosage in living
cells in real time. Our platform is based on the application of
Control Engineering to biological systems (a field named cyber-
genetics), and it represents a significant advance compared with
previous studies assaying a-synuclein inclusion formation and
clearance. Recently, a microfluidics device has been built to
generate a chemical gradient resulting in nine different concen-
trations of galactose (or other small molecules) to induce
different a-synuclein levels in a yeast PD model, but no inclu-
sions were observed by galactose administration alone (Fer-
nandes et al., 2014). Previous studies have also investigated
clearance of WT a-synuclein inclusions in the yeast PD model,924 Cell Reports 27, 916–927, April 16, 2019suggesting an involvement of autophagy (Petroi et al., 2012;
Popova et al., 2015). However, the phenomenon was not quan-
titatively investigated at the single-cell level.
Here, we performed the detailed single-cell quantitative char-
acterization of the yeast PDmodel and demonstrated that forma-
tion of inclusions in both WT and A53T mutant a-synuclein yeast
strains is strictly concentration dependent, in agreement with
previous results obtained in cell-free models (Iljina et al., 2016).
Moreover, we precisely measured the in vivo aggregation
threshold in both strains and demonstrated that the A53T muta-
tion causes the threshold to become about half of the WT
a-synuclein threshold (Figure 4; Table S4), and that if a cell
expresses the A53T protein above the threshold it will form
inclusions with 86% probability (i.e., the accuracy of the classi-
fier in Table S4).
In addition, whereas the cell cycle slows down in the presence
of inclusions and eventually stops (Figure 4E), there is not a
quantitative difference between WT and A53T a-synuclein,
implying that the increased toxicity observed in yeast growth
assays has to be attributed uniquely to the lower aggregation
threshold of A53T.
We chemically modulated the proteasomal and autophagic
pathways to dissect their contribution to a-synuclein inclusions’
clearance. We quantitatively characterized clearance dynamics
at the population level and at the single-cell level for two different
concentrations of A53T a-synuclein, both below and above the
aggregation threshold. We found that: (1) enhancing autophagy
speeds up A53T a-synuclein inclusions’ clearance, whereas
repression of autophagy impairs it, with proteasome inhibition
causing an intermediate effect; and (2) autophagy modulation
has no effect on A53T a-synuclein clearance dynamics when
its expression is below the aggregation threshold, and thus
when inclusions are not present. By performing a detailed sin-
gle-cell quantitative analysis of clearance dynamics, we demon-
strated that the time it takes for the cell to bud following inhibition
of A53T a-synuclein expression is the parameter most affected
by autophagy modulation, whereas once cell division occurs,
dilution is the main driver of inclusion clearance in all conditions
tested. This means that autophagy exerts its beneficial effects in
yeast before cell division occurs, enabling the cell to divide. This
finding may impact the way the PD yeast model will be used for
studying disease mechanisms and for screening drugs and
targets. For example, the readout of most chemical and genetic
screens in the yeast PD model is number of colonies formed in
galactose, when inclusions are present. This phenotype can be
measured only at the population level and requires considerable
time to allow for colonies to become visible. We propose instead
to adopt the TFB as the screening parameter to evaluate the
efficacy of genetic and chemical perturbation, because it can
be measured in single cells over a shorter period of time.
Our results show that the formation of inclusions in yeast is a
phase-transition-like phenomenon, suggesting that inclusions
form in equilibrium with a-synuclein monomers and thus should
‘‘passively’’ dissolve as a-synuclein concentration decreases
below the aggregation threshold, unlike the insoluble amyloid
aggregates found in Lewy bodies. We demonstrated that rapa-
mycin treatment can considerably speed up inclusion clearance
in yeast. This phenomenonmay be explained either by assuming
that inclusions in yeast are actively degraded by autophagy, or
by the effect of rapamycin on translational repression, which re-
duces the amount of the available a-synuclein protein, or still by
other indirect effects. However, when we treated cells with the
vacuole protease inhibitor PMSF, inclusion clearance was
considerably delayed, thus suggesting that active degradation
by autophagy is the main player.
Protein aggregation plays key roles in cellular processes as
wide ranging as disease initiation and progression, signaling,
and evolution. Automated microfluidics feedback control repre-
sents a technology to quantitatively probe the phenomena linked
to protein dosage. Moreover, we recently demonstrated that a
similar microfluidics platform can be used to regulate protein
expression in mammalian cells (Postiglione et al., 2018), sug-
gesting the possibility of performing similar quantitative studies
in human neuronal cell lines in the near future. Our approach
can be easily extended to unravel the dynamics of other proteins
prone to aggregation, such as the tau protein.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILSB Yeast Strains and Growth Conditions
d METHOD DETAILS
B Plasmid Construction
B Strain Construction
B Spotting Assays
B Microfluidics
B Phase Contrast and Epifluorescence Microscopy
B Image Processing
B Feedback Control Strategy
B Experimental Setup
B Treatments for Inclusions’ Clearance Experiments
d QUANTIFICATION AND STATISTICAL ANALYSIS
B Normalization of a-Synuclein Expression Level
B Single-Cell Analysis of Control Experiments
B Aggregation Threshold Estimation
B Single-Cell Analysis of Inclusions’ Clearance
B Mathematical Model of Fluorescence Drop at Division
B Model Prediction Error of Fluorescence Drop at Divi-
sion
B Correlation Analysis between Time-to-First-Bud and
Inclusions’ Clearance Time
d DATA AND SOFTWARE AVAILABILITY
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.
celrep.2019.03.081.
ACKNOWLEDGMENTS
Wewould like to thank J. Hasty (UCSD, USA) for the master mold of the micro-
fluidic device and S. Lindquist lab (Whitehead Institute for BiomedicalResearch, USA) for a-synuclein plasmids. This work was supported partly
by Fondazione Telethon (grant TGM16SB1) and partly by the COSY-BIO (Con-
trol Engineering of Biological Systems for Reliable Synthetic Biology Applica-
tions) project, which has received funding from the European Union’s Horizon
2020 research and innovation programme under grant agreement 766840.
AUTHOR CONTRIBUTIONS
G.P. designed and performed the experiments. C.W. generated the yeast
strains. M.S. helped with molecular cloning. G.P. and D.d.B. analyzed the
data. D.d.B. conceived the idea and supervised the work. G.P., C.W., and
D.d.B. wrote the manuscript.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: April 25, 2018
Revised: February 20, 2019
Accepted: March 22, 2019
Published: April 16, 2019
SUPPORTING CITATIONS
The following references appear in the Supplemental Information: Gietz and
Sugino (1998); Janke et al. (2004); Taxis and Knop (2006).
REFERENCES
Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I.,
Shah, B., Weir, D., Thompson, C., Szu-Tu, C., Trinh, J., et al. (2013). Alpha-
synuclein p.H50Q, a novel pathogenic mutation for Parkinson’s disease.
Mov. Disord. 28, 811–813.
Auluck, P.K., Caraveo, G., and Lindquist, S. (2010). a-Synuclein: membrane in-
teractions and toxicity in Parkinson’s disease. Annu. Rev. Cell Dev. Biol. 26,
211–233.
Breker, M., Gymrek, M., and Schuldiner, M. (2013). A novel single-cell
screening platform reveals proteome plasticity during yeast stress responses.
J. Cell Biol. 200, 839–850.
Buell, A.K., Galvagnion, C., Gaspar, R., Sparr, E., Vendruscolo, M., Knowles,
T.P.J., Linse, S., and Dobson, C.M. (2014). Solution conditions determine
the relative importance of nucleation and growth processes in a-synuclein
aggregation. Proc. Natl. Acad. Sci. USA 111, 7671–7676.
Camacho, E.F., and Alba, C.B. (2007). Model Predictive Control (Springer-
Verlag).
Chait, R., Ruess, J., Bergmiller, T., Tkacik, G., and Guet, C.C. (2017). Shaping
bacterial population behavior through computer-interfaced control of individ-
ual cells. Nat. Commun. 8, 1535.
Charvin, G., Cross, F.R., and Siggia, E.D. (2009). Forced periodic expression of
G1 cyclins phase-locks the budding yeast cell cycle. Proc. Natl. Acad. Sci.
USA 106, 6632–6637.
Chen, Y.-C., Farzadfard, F., Gharaei, N., Chen, W.C.W., Cao, J., and Lu, T.K.
(2017). Randomized CRISPR-Cas Transcriptional Perturbation Screening
Reveals Protective Genes against Alpha-Synuclein Toxicity. Mol. Cell 68,
247–257.e5.
Cohen, S.I.A., Vendruscolo, M., Welland, M.E., Dobson, C.M., Terentjev, E.M.,
and Knowles, T.P.J. (2011). Nucleated polymerization with secondary path-
ways. I. Time evolution of the principal moments. J. Chem. Phys. 135, 065105.
Cohen, S.I.A., Vendruscolo, M., Dobson, C.M., and Knowles, T.P.J. (2012).
From macroscopic measurements to microscopic mechanisms of protein
aggregation. J. Mol. Biol. 421, 160–171.
Collins, G.A., Gomez, T.A., Deshaies, R.J., and Tansey, W.P. (2010). Com-
bined chemical and genetic approach to inhibit proteolysis by the proteasome.
Yeast 27, 965–974.Cell Reports 27, 916–927, April 16, 2019 925
Conway, K.A., Harper, J.D., and Lansbury, P.T. (1998). Accelerated in vitro
fibril formation by a mutant a-synuclein linked to early-onset Parkinson dis-
ease. Nat. Med. 4, 1318–1320.
Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar, B., Liu,
K., Xu, K., Strathearn, K.E., Liu, F., et al. (2006). a-Synuclein blocks ER-Golgi
traffic and Rab1 rescues neuron loss in Parkinson’s models. Science 313,
324–328.
Delorme-Axford, E., Guimaraes, R.S., Reggiori, F., and Klionsky, D.J. (2015).
The yeast Saccharomyces cerevisiae: an overview of methods to study auto-
phagy progression. Methods 75, 3–12.
Elowitz, M.B., Levine, A.J., Siggia, E.D., and Swain, P.S. (2002). Stochastic
gene expression in a single cell. Science 297, 1183–1186.
Ernst, R., Klemm, R., Schmitt, L., and Kuchler, K. (2005). Yeast ATP-binding
cassette transporters: cellular cleaning pumps. Methods Enzymol. 400,
460–484.
Farrer, M., Kachergus, J., Forno, L., Lincoln, S., Wang, D.-S., Hulihan, M., Mar-
aganore, D., Gwinn-Hardy, K., Wszolek, Z., Dickson, D., and Langston, J.W.
(2004). Comparison of kindreds with parkinsonism and alpha-synuclein
genomic multiplications. Ann. Neurol. 55, 174–179.
Fernandes, J.T.S., Tenreiro, S., Gameiro, A., Chu, V., Outeiro, T.F., and Conde,
J.P. (2014). Modulation of alpha-synuclein toxicity in yeast using a novelmicro-
fluidic-based gradient generator. Lab Chip 14, 3949–3957.
Ferry, M.S., Razinkov, I.A., and Hasty, J. (2011). Microfluidics for synthetic
biology: from design to execution. Methods Enzymol. 497, 295–372.
Fiore, G., Perrino, G., di Bernardo, M., and di Bernardo, D. (2016). In Vivo Real-
Time Control of Gene Expression: A Comparative Analysis of Feedback
Control Strategies in Yeast. ACS Synth. Biol. 5, 154–162.
Flagmeier, P., Meisl, G., Vendruscolo, M., Knowles, T.P.J., Dobson, C.M.,
Buell, A.K., and Galvagnion, C. (2016). Mutations associated with familial
Parkinson’s disease alter the initiation and amplification steps of a-synuclein
aggregation. Proc. Natl. Acad. Sci. USA 113, 10328–10333.
Franklin, G.F., Powell, J.D., and Workman, M.L. (1990). Digital Control of
Dynamic Systems (Addison-Wesley Longman Publishing Co., Inc.).
Fusco, G., Pape, T., Stephens, A.D., Mahou, P., Costa, A.R., Kaminski, C.F.,
Kaminski Schierle, G.S., Vendruscolo, M., Veglia, G., Dobson, C.M., and
De Simone, A. (2016). Structural basis of synaptic vesicle assembly promoted
by a-synuclein. Nat. Commun. 7, 12563.
Galvagnion, C., Buell, A.K., Meisl, G., Michaels, T.C.T., Vendruscolo, M.,
Knowles, T.P.J., and Dobson, C.M. (2015). Lipid vesicles trigger a-synuclein
aggregation by stimulating primary nucleation. Nat. Chem. Biol. 11,
229–234.
Galvagnion, C., Brown, J.W.P., Ouberai, M.M., Flagmeier, P., Vendruscolo, M.,
Buell, A.K., Sparr, E., and Dobson, C.M. (2016). Chemical properties of lipids
strongly affect the kinetics of the membrane-induced aggregation of a-synu-
clein. Proc. Natl. Acad. Sci. USA 113, 7065–7070.
Garcia, G.A., Cohen, S.I.A., Dobson, C.M., and Knowles, T.P.J. (2014). Nucle-
ation-conversion-polymerization reactions of biological macromolecules
with prenucleation clusters. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 89,
032712.
Giasson, B.I., Uryu, K., Trojanowski, J.Q., and Lee, V.M.-Y. (1999). Mutant and
wild type human a-synucleins assemble into elongated filaments with distinct
morphologies in vitro. J. Biol. Chem. 274, 7619–7622.
Giehm, L., Lorenzen, N., and Otzen, D.E. (2011). Assays for a-synuclein aggre-
gation. Methods 53, 295–305.
Gietz, R.D., and Sugino, A. (1988). New yeast-Escherichia coli shuttle vectors
constructed with in vitro mutagenized yeast genes lacking six-base pair re-
striction sites. Gene 74, 527–534.
Goedert, M., Spillantini, M.G., Del Tredici, K., and Braak, H. (2013). 100 years
of Lewy pathology. Nat. Rev. Neurol. 9, 13–24.
Goedert, M., Jakes, R., and Spillantini, M.G. (2017). The synucleinopathies:
twenty years on. J. Parkinsons Dis. 7 (Suppl 1), S51–S69.926 Cell Reports 27, 916–927, April 16, 2019Iba´n˜ez, P., Bonnet, A.-M., De´barges, B., Lohmann, E., Tison, F., Pollak, P.,
Agid, Y., D€urr, A., and Brice, A. (2004). Causal relation between a-synuclein
gene duplication and familial Parkinson’s disease. Lancet 364, 1169–1171.
Iljina, M., Garcia, G.A., Horrocks, M.H., Tosatto, L., Choi, M.L., Ganzinger,
K.A., Abramov, A.Y., Gandhi, S., Wood, N.W., Cremades, N., et al. (2016).
Kinetic model of the aggregation of alpha-synuclein provides insights into
prion-like spreading. Proc. Natl. Acad. Sci. USA 113, E1206–E1215.
Ingelsson, M. (2016). Alpha-Synuclein Oligomers-Neurotoxic Molecules in
Parkinson’s Disease and Other Lewy Body Disorders. Front. Neurosci. 10,
408.
Janke, C., Magiera, M.M., Rathfelder, N., Taxis, C., Reber, S., Maekawa, H.,
Moreno-Borchart, A., Doenges, G., Schwob, E., Schiebel, E., and Knop, M.
(2004). A versatile toolbox for PCR-based tagging of yeast genes: new fluores-
cent proteins, more markers and promoter substitution cassettes. Yeast 21,
947–962.
Jonas, F., Soifer, I., and Barkai, N. (2018). A Visual Framework for Classifying
Determinants of Cell Size. Cell Rep. 25, 3519–3529.e2.
Kamada, Y., Sekito, T., and Ohsumi, Y. (2004). Autophagy in yeast: a TOR-
mediated response to nutrient starvation. Curr. Top. Microbiol. Immunol.
279, 73–84.
Kiely, A.P., Asi, Y.T., Kara, E., Limousin, P., Ling, H., Lewis, P., Proukakis, C.,
Quinn, N., Lees, A.J., Hardy, J., et al. (2013). a-Synucleinopathy associated
with G51D SNCA mutation: a link between Parkinson’s disease and multiple
system atrophy? Acta Neuropathol. 125, 753–769.
Koprich, J.B., Kalia, L.V., and Brotchie, J.M. (2017). Animal models of a-synu-
cleinopathy for Parkinson disease drug development. Nat. Rev. Neurosci. 18,
515–529.
Kr€uger, R., Kuhn, W., M€uller, T., Woitalla, D., Graeber, M., Ko¨sel, S., Przuntek,
H., Epplen, J.T., Scho¨ls, L., andRiess, O. (1998). Ala30Promutation in the gene
encoding a-synuclein in Parkinson’s disease. Nat. Genet. 18, 106–108.
La´zaro, D.F., Pavlou, M.A.S., and Outeiro, T.F. (2017). Cellular models as tools
for the study of the role of alpha-synuclein in Parkinson’s disease. Exp. Neurol.
298 (Pt B), 162–171.
Lee, D.H., and Goldberg, A.L. (1998). Proteasome inhibitors: valuable new
tools for cell biologists. Trends Cell Biol. 8, 397–403.
Lee, H.-J., Choi, C., and Lee, S.-J. (2002). Membrane-bound a-synuclein has a
high aggregation propensity and the ability to seed the aggregation of the cyto-
solic form. J. Biol. Chem. 277, 671–678.
Lorenzen, N., Nielsen, S.B., Buell, A.K., Kaspersen, J.D., Arosio, P., Vad, B.S.,
Paslawski, W., Christiansen, G., Valnickova-Hansen, Z., Andreasen, M., et al.
(2014). The role of stable a-synuclein oligomers in the molecular events under-
lying amyloid formation. J. Am. Chem. Soc. 136, 3859–3868.
Martikainen, M.H., Pa¨iva¨rinta, M., Hietala, M., and Kaasinen, V. (2015). Clinical
and imaging findings in Parkinson disease associated with the A53E SNCA
mutation. Neurol. Genet. 1, e27.
Menezes, R., Tenreiro, S., Macedo, D., Santos, C.N., and Outeiro, T.F. (2015).
From the baker to the bedside: yeast models of Parkinson’s disease. Microb.
Cell 2, 262–279.
Menolascina, F., Fiore, G., Orabona, E., De Stefano, L., Ferry, M., Hasty, J., di
Bernardo, M., and di Bernardo, D. (2014). In-vivo real-time control of protein
expression from endogenous and synthetic gene networks. PLoS Comput.
Biol. 10, e1003625.
Milias-Argeitis, A., Rullan, M., Aoki, S.K., Buchmann, P., and Khammash, M.
(2016). Automated optogenetic feedback control for precise and robust
regulation of gene expression and cell growth. Nat. Commun. 7, 12546.
Outeiro, T.F., and Lindquist, S. (2003). Yeast cells provide insight into alpha-
synuclein biology and pathobiology. Science 302, 1772–1775.
Pannocchia, G., and Rawlings, J.B. (2003). Disturbance models for offset-free
model-predictive control. AIChE J. 49, 426–437.
Pasanen, P., Myllykangas, L., Siitonen, M., Raunio, A., Kaakkola, S., Lyytinen,
J., Tienari, P.J., Po¨yho¨nen, M., and Paetau, A. (2014). Novel a-synuclein
mutation A53E associated with atypical multiple system atrophy and
Parkinson’s disease-type pathology. Neurobiol. Aging 35, 2180.e1–2180.e5.
Pedraza, J.M., and van Oudenaarden, A. (2005). Noise propagation in gene
networks. Science 307, 1965–1969.
Perrino, G., Wilson, C., Santorelli, M., and di Bernardo, D. (2016). Control of
gene expression for the study of neurodegenerative disorders: a proof-of-
principle experimental study. IFAC-Papers OnLine. 49, 8–13.
Petroi, D., Popova, B., Taheri-Talesh, N., Irniger, S., Shahpasandzadeh, H.,
Zweckstetter, M., Outeiro, T.F., and Braus, G.H. (2012). Aggregate clearance
of a-synuclein in Saccharomyces cerevisiae depends more on autophago-
some and vacuole function than on the proteasome. J. Biol. Chem. 287,
27567–27579.
Polymenis, M., and Aramayo, R. (2015). Translate to divide: sontrol of the cell
cycle by protein synthesis. Microb. Cell 2, 94–104.
Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A.,
Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997). Mutation in the
a-synuclein gene identified in families with Parkinson’s disease. Science
276, 2045–2047.
Popova, B., Kleinknecht, A., and Braus, G.H. (2015). Posttranslational Modifi-
cations and Clearing of a-Synuclein Aggregates in Yeast. Biomolecules 5,
617–634.
Postiglione, L., Napolitano, S., Pedone, E., Rocca, D.L., Aulicino, F., Santorelli,
M., Tumaini, B., Marucci, L., and di Bernardo, D. (2018). Regulation of Gene
Expression and Signaling Pathway Activity in Mammalian Cells by Automated
Microfluidics Feedback Control. ACS Synth. Biol. 7, 2558–2565.
Proukakis, C., Dudzik, C.G., Brier, T., MacKay, D.S., Cooper, J.M., Millhauser,
G.L., Houlden, H., and Schapira, A.H. (2013). A novel a-synuclein missense
mutation in Parkinson disease. Neurology 80, 1062–1064.
Raser, J.M., and O’Shea, E.K. (2004). Control of stochasticity in eukaryotic
gene expression. Science 304, 1811–1814.
Rea, D., Perrino, G., di Bernardo, D., Marcellino, L., and Romano, D. (2018). A
GPU algorithm for tracking yeast cells in phase-contrast microscopy images.
Int. J. High Perform. Comput. Appl. Published online September 24, 2018.
https://doi.org/10.1177/1094342018801482.
Rosenfeld, N., Young, J.W., Alon, U., Swain, P.S., and Elowitz, M.B. (2005).
Gene regulation at the single-cell level. Science 307, 1962–1965.
Sancenon, V., Lee, S.-A., Patrick, C., Griffith, J., Paulino, A., Outeiro, T.F., Re-
ggiori, F., Masliah, E., andMuchowski, P.J. (2012). Suppression of a-synuclein
toxicity and vesicle trafficking defects by phosphorylation at S129 in yeast de-
pends on genetic context. Hum. Mol. Genet. 21, 2432–2449.
Schneider, K.L., Nystro¨m, T., and Widlund, P.O. (2018). Studying Spatial Pro-
tein Quality Control, Proteopathies, and Aging Using Different Model Misfold-
ing Proteins in S. cerevisiae. Front. Mol. Neurosci. 11, 249.
Sharon, R., Bar-Joseph, I., Frosch, M.P., Walsh, D.M., Hamilton, J.A., and Sel-
koe, D.J. (2003). The formation of highly soluble oligomers of a-synuclein isregulated by fatty acids and enhanced in Parkinson’s disease. Neuron 37,
583–595.
Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus,
J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003). a-Synu-
clein locus triplication causes Parkinson’s disease. Science 302, 841.
Soper, J.H., Roy, S., Stieber, A., Lee, E., Wilson, R.B., Trojanowski, J.Q., Burd,
C.G., and Lee, V.M. (2008). a-Synuclein-induced aggregation of cytoplasmic
vesicles in Saccharomyces cerevisiae. Mol. Biol. Cell 19, 1093–1103.
Takeshige, K., Baba, M., Tsuboi, S., Noda, T., and Ohsumi, Y. (1992). Auto-
phagy in yeast demonstrated with proteinase-deficient mutants and condi-
tions for its induction. J. Cell Biol. 119, 301–311.
Taxis, C., and Knop, M. (2006). System of centromeric, episomal, and integra-
tive vectors based on drug resistance markers for Saccharomyces cerevisiae.
Biotechniques 40, 73–78.
Tenreiro, S., Reim~ao-Pinto, M.M., Antas, P., Rino, J., Wawrzycka, D., Macedo,
D., Rosado-Ramos, R., Amen, T., Waiss, M., Magalh~aes, F., et al. (2014).
Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast
model of Parkinson’s disease. PLoS Genet. 10, e1004302.
Uhlendorf, J., Miermont, A., Delaveau, T., Charvin, G., Fages, F., Bottani, S.,
Batt, G., and Hersen, P. (2012). Long-term model predictive control of gene
expression at the population and single-cell levels. Proc. Natl. Acad. Sci.
USA 109, 14271–14276.
Visanji, N.P., Brotchie, J.M., Kalia, L.V., Koprich, J.B., Tandon, A., Watts, J.C.,
and Lang, A.E. (2016). a-Synuclein-Based Animal Models of Parkinson’s
Disease: Challenges and Opportunities in a New Era. Trends Neurosci. 39,
750–762.
Volfson, D., Marciniak, J., Blake, W.J., Ostroff, N., Tsimring, L.S., and Hasty, J.
(2006). Origins of extrinsic variability in eukaryotic gene expression. Nature
439, 861–864.
Webb, J.L., Ravikumar, B., Atkins, J., Skepper, J.N., and Rubinsztein, D.C.
(2003). a-Synuclein is degraded by both autophagy and the proteasome.
J. Biol. Chem. 278, 25009–25013.
Wislet-Gendebien, S., D’Souza, C., Kawarai, T., St George-Hyslop, P., West-
away, D., Fraser, P., and Tandon, A. (2006). Cytosolic proteins regulate
a-synuclein dissociation from presynaptic membranes. J. Biol. Chem. 281,
32148–32155.
Zabrocki, P., Bastiaens, I., Delay, C., Bammens, T., Ghillebert, R., Pellens, K.,
De Virgilio, C., Van Leuven, F., and Winderickx, J. (2008). Phosphorylation,
lipid raft interaction and traffic of a-synuclein in a yeast model for Parkinson.
Biochim. Biophys. Acta 1783, 1767–1780.
Zarranz, J.J., Alegre, J., Go´mez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero,
I., Vidal, L., Hoenicka, J., Rodriguez, O., Atare´s, B., et al. (2004). The new mu-
tation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.
Ann. Neurol. 55, 164–173.Cell Reports 27, 916–927, April 16, 2019 927
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Chemicals, Peptides, and Recombinant Proteins
Rapamycin from Streptomyces hygroscopicus Sigma-Aldrich Cat#R0395-1mg
MG132 Calbiochem Cat#474791
PMSF Sigma-Aldrich CAS: 329-98-6
Deposited Data
Zenodo data repository This study https://doi.org/10.5281/zenodo.2546466
Experimental Models: Organisms/Strains
Yeast strains Table S1 Table S1
Recombinant DNA
Plasmids Table S2 Table S2
Software and Algorithms
MATLAB The MathWorks N/A
R The R Foundation N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Diego di
Bernardo (dibernardo@tigem.it).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Yeast Strains and Growth Conditions
All Saccharomyces cerevisiae strains used in this study are listed in Table S1. For all experimental conditions, cells were cultured at
30 C in synthetic complete drop-out media, composed of yeast nitrogen base ð0:67% w=vÞwith all amino acids except leucine, sup-
plemented with either glucose ð2% w=vÞ, or raffinose ð2% w=vÞ, or galactose ð2% w=vÞ and raffinose ð2% w=vÞ.
METHOD DETAILS
Plasmid Construction
All plasmids used in this study are listed in Table S2. WT and A53T a-synuclein expression cassettes were amplified from pRS304-
aSynWT-GFP and pRS304-aSynA53T-GFP, respectively, (a kind gift from S. Lindquist lab) via PCR and cloned into both pYM27
(kanamycin selection) and pYM25 (hygromycin selection) between SalI and BglII restriction sites or into the centromeric plasmid YC-
plac111. All plasmid sequences were checked by Sanger sequencing.
Strain Construction
All yeast strains used are listed in Table S1. The strain constitutively expressing mCherry was derived from a strain with TEF2pr-
mCherry::URA3 integrated into the URA3 locus (Breker et al., 2013). The aSyn expression cassettes were PCR-amplified from
the pYM27 and pYM25 constructs using oligonucleotides containing sequences homologous to the 50 and 30 UTR of the
dubious ORFs YMR082C or YFR054C, respectively. Strain yDdB001 (expressing mCherry) was transformed sequentially with
the respective amplicons using standard procedures. Correct integrations were verified by PCR on extracted genomic DNA.
The multiple copy WT a-synuclein strain contains two integrated WT a-synuclein expression cassettes (YMR082CD::GAL1p-
SNCA-GFP-KanMX and YFR054CD::GAL1p-SNCA-GFP-HphMX) and at least one copy expressed from a yeast centromeric
plasmid (YCplac111-GAL1p-SNCA-GFP-LEU2). The multiple copy A53T a-synuclein strain contains two integrated A53T
a-synuclein expression cassettes (YMR082CD::GAL1p-sncaA53T-GFP-KanMX and YFR054CD::GAL1p-sncaA53T-GFP-
HphMX) and at least one copy expressed from a yeast centromeric plasmid (YCplac111-GAL1p-sncaA53T-GFP-LEU2).
Deletion of the Pdr5 gene was performed by amplifying the natNH2 gene (nourseothricin selection) from plasmid pRS41N using
oligonucleotides containing sequences homologous to the 50 and 30 UTR of the Pdr5 gene, followed by transformation of the
multiple copy A53T a-synuclein strain.e1 Cell Reports 27, 916–927.e1–e5, April 16, 2019
Spotting Assays
Cells from a frozen glycerol stock ð80 CÞwere resuspended in 1mL of growthmedia supplemented with glucose ð2% w=vÞ, grown
in a shaking incubator at 220 r:p:m: and 30 C to log phase. The cells were diluted to the concentration of OD600 = 0:1 ð 33
106cells=mLÞ, and then ten-fold serially diluted and spotted onto synthetic complete drop-out media plates supplemented either
with glucose (uninduced; 2% w=v) or galactose (induced; 2% w=v). Plates were incubated at 30 C for 3 days.
Microfluidics
All microfluidics experiments were performed by means of the MFD0005a device (Ferry et al., 2011). This device contains a chamber
in which the yeast cells are trapped. The height of the chamber ð3:5 mmÞ allows the yeast cells to grow only in amonolayer, simplifying
the image analysis process. Microfluidic devices were fabricated with a replica molding technique. The master-mold was produced
using multilayer soft-lithography with SU-8 as photoresist. Before the fabrication, the master-mold was exposed to vapors of chlor-
otrimethylsilane (CARLO ERBAReagents) for 10min in order to create an anti-sticking layer for polydimethylsiloxane (PDMS; Sylgard
184, Dow Corning). The PDMS was poured on the top of the master-mold with a 1 : 10 ratio (curing agent to base; w=w) and then
cured at 80 C for 2 hrs. Next, the PDMS layer was cut and peeled from the master-mold. The inlet ports of the PDMS device
were pierced with a micro-puncher (0:5mm; World Precision Instruments), and then the PDMS device was washed overnight in
isopropyl alcohol. A cover glass (thickness no. 1.5; Marienfeld-Superior) was first cleaned in acetone, then washed in ddH2O,
and finally cleaned in isopropyl alcohol. The PDMS device and the cover glass were left overnight to dry, and then bonded together
irreversibly by undergoing a plasma treatment for 1min in a plasma cleaner machine (ZEPTO version B; Diener electronic). The
bonded device was baked for 2 hrs at 80 C, and then stored at 4 C until use. The fluid that reaches the chamber of the microfluidic
device is a mixture of the growth media coming from the two inlet ports of the microfluidic device. The blending of the growth media
depends on the relative pressure between the two fluids at the inlet ports. In order to change the relative pressure, we devised an
automated actuation system that varies the relative height of the two syringes filled with the inducing/uninducing media. The actu-
ation system relies on two custom vertically mounted linear actuators, that are conceived to move independently. Each linear
actuator comprises a stepper motor that realizes the motion of the syringe through a timing belt and two pulleys. A customMATLAB
script pilots the stepper motors in order to realize the galactose pulse according to the computed control input.
Phase Contrast and Epifluorescence Microscopy
Phase contrast and epifluorescence images were acquired at 5 min intervals at 40 3 magnification (CFI Plan Fluor DLL 40 3 dry
objective, NA 0.75; Nikon Instruments) using an Eclipse Ti-E inverted microscope (Nikon Instruments) coupled with an EMCCD
camera (iXon Ultra 897; Andor Technology) and a Perfect Focus System (Nikon Instruments). The microfluidic device was placed
on the microscope stage within a 30C incubator system. Appropriate filters were used for acquiring the green (Piston GFP; Nikon
Instruments) and the red (TRITC HYQ; Nikon Instruments) fluorescence channels. Time-lapse acquisition was controlled by the
NIS-Elements Advanced Research software (Nikon Instruments). Raw phase contrast and epifluorescence images were processed
using custom MATLAB software. The procedures to quantify the a-synuclein expression levels among the time-lapse experiments
are described below.
Image Processing
The procedures for quantifying the a-synuclein expression levels were performed using custom scripts in the MATLAB environment.
Yeast cells were localized by processing the phase contrast images with a custom segmentation algorithm. Raw phase contrast
images were enhanced by using the MATLAB function imadjust of the Image Processing Toolbox. A Gaussian low pass filter was first
designed with the MATLAB function fspecial of the Image Processing Toolbox, and then applied to the enhanced images with the
MATLAB function imfilter of the Image Processing Toolbox. Next, yeast cells were found in the processed phase contrast images
by using the circular Hough Transform. The circular Hough Transform detects the circles in the image, and it is implemented by
the MATLAB function imfindcircles of the Image Processing Toolbox. The function returns a two-column matrix containing the
centroids of the yeasts found in the phase contrast images, and the radii associated to each centroid. Such information was em-
ployed to create a binary mask that defines the pixels of the fluorescence images associated to the yeast cells. Fluorescence
intensities were quantified by processing the fluorescence images (green channel and red channel) with the binary masks described
above and a custom MATLAB script. Average fluorescence levels were computed by integrating the signals from the selected
pixels. Small rectangular regions outside the microfluidic chamber were used to eliminate the basal fluorescence levels. The basal
fluorescence levels were first computed by integrating the fluorescence signals emitted by the pixels belonging to these regions, and
then subtracted from the average fluorescence levels. Note that the fluorescence intensities aremeasured in arbitrary units. Evolution
of single cells were tracked using a custom MATLAB script. The script comprises a tracking module that searches the correspon-
dences between the objects (i.e., the centroids) detected in two consecutive phase contrast images by minimizing a cost
configuration (i.e., the displacements among the centroids of two consecutive images) and a lineage analysis module that
builds a genealogical tree containing the mother-daughter relationships among the yeast cells. Since the tracking module is compu-
tationally expensive to be executed in real-time, a GPU-parallel software implementation of the tracking module was developed
(Rea et al., 2018).Cell Reports 27, 916–927.e1–e5, April 16, 2019 e2
Feedback Control Strategy
All control experiments were performed by means of a model predictive control (MPC) algorithm, which has been successfully
applied to control gene expression and protein activation in yeast (Chait et al., 2017; Fiore et al., 2016; Milias-Argeitis et al., 2016;
Uhlendorf et al., 2012). MPC is an optimization-based technique which uses a dynamical model to predict the future behavior of
the controlled system in order to compute the best control input to steer the system output toward the desired reference (Camacho
and Alba, 2007). The MPC algorithm was implemented as previously described unless otherwise specified (Fiore et al., 2016). In our
system, at each sampling time kT, MPC computes the optimal duration d of the galactose pulse (ranging from 0 min to 5 min,
assuming a period T equals to 5 min) needed to minimize a cost index (SSE, sum of the predicted squared control error) over a
prediction horizon TP ð2 hrsÞ. The control error e is defined as the difference between the desired a-synuclein level yref and the
measured (or predicted, as in the case of theMPC algorithm) a-synuclein level y. Optimization was performedwith theMATLAB func-
tion fmincon of the Optimization Toolbox. Sequential Quadratic Programming (SQP) was used as solver method. The dynamical
model used by the MPC algorithm consists of three difference linear equations:
x1ðk + 1Þ= a11 x1ðkÞ+ a12 x2ðkÞ+b1 uðkÞx2ðk + 1Þ= a21 x1ðkÞ+ a22 x2ðkÞ+b2 uðkÞx3ðk + 1Þ= x3ðkÞ
and a further equation that describes the system output:
yðkÞ= c1 x1ðkÞ+ c2 x2ðkÞ+ x3ðkÞ
In the above equations, xi˛<3represents the system state, which has no physical meaning in our model. Instead, u represents the
control input, and it is mathematically described as:
uðkÞ =dðkÞ
T
Since d%T0u˛½0; 1. We thus assumed that the control input is piecewise constant during the period T (zero-order hold method)
(Franklin et al., 1990). Moreover, the state variable x3 augments the order of the dynamical model in order to reduce the steady-state
error (Pannocchia and Rawlings, 2003). State system is numerically estimated from the measured fluorescence data by using a
Kalman filter. Model parameters used in this study are reported in Table S3. The MPC algorithm was implemented by custom scripts
in the MATLAB environment.
Experimental Setup
Formicrofluidics control experiments (Figures 2, 3, and S3), cells from a frozen glycerol stock ð80 CÞwere resuspended in 10mL
of growth medium supplemented with raffinose ð2% w=vÞ, grown overnight in a shaking incubator at 220 r:p:m: and 30 C; poured
in a 50mL syringe (BD), and then injected in the microfluidic device as previously described (Fiore et al., 2016). Unless otherwise
specified, cells were left to settle in the chamber for 15 min with growth medium supplemented with glucose ð2% w=vÞ. Image
acquisition was then launched, as well as the custom software for running the time-lapse control experiment. At the beginning
of the experiment, a region of interest (ROI) was selected on the first phase contrast image. The ROI defines the area containing
the cellular population that has to be segmented and whose fluorescence signals have to be quantified. Indeed, all custom
software considers only cells inside this area. Outside the chamber another area is selected on the first phase contrast image,
that defines the background to quantify the basal fluorescence levels in each fluorescence channel. For single-cell control exper-
iments (Figure 5), the cell to be controlled was chosen randomly at the end of the initial calibration phase (15 min in growth medium
supplemented with glucose). For inclusions’ clearance experiments (Figure 6), cells from a frozen glycerol stock ð80 CÞ were
resuspended in 10mL of growth medium supplemented with raffinose ð2% w=vÞ and galactose ð2% w=vÞ, grown overnight in a
shaking incubator at 220 r:p:m: and 30 C; poured in a 50mL syringe (BD), and then injected in the microfluidic device as
previously described (Fiore et al., 2016). Cells were left to settle in the chamber for 10 min with growth medium supplemented
with galactose ð2% w=vÞ and raffinose ð2% w=vÞ. Image acquisition was then launched. After 10 min, galactose and raffinose
were replaced by glucose ð2% w=vÞ. For all microfluidics experiments, the experimental platform was initialized as previously
described (Fiore et al., 2016).
Treatments for Inclusions’ Clearance Experiments
Three compounds were used to study the clearance of a-synuclein inclusions: (i) rapamycin at a concentration of 100 nM, (ii) phenyl-
methane-sulfonyl-fluoride (PMSF) at a concentration of 1mM, and (iii) MG132 (also known as carbobenzoxy-Leu-Leu-leucinal) at a
concentration of 50 mM. All the compounds were added to the growth medium supplemented with glucose.e3 Cell Reports 27, 916–927.e1–e5, April 16, 2019
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical details are provided in the figure legends unless otherwise specified. The a-synuclein concentrations in both Figures 2 and
3 are presented as means ± standard deviations. Quantification and statistical analysis of the single-cell aggregation analysis were
performed in the MATLAB environment. The statistical comparisons were made using the Student’s t test. In these analyses, a
p value < 0:05 was considered to be statistically significant. Quantification and statistical analysis of the inclusions’ clearance
analysis were performed in the R environment. The statistical comparisons were made using the Conover-Iman test of multiple
comparisons using rank sums, available in the conover.test package. Biological significance is defined as a fold change greater
than 10% for the median values between conditions.
Normalization of a-Synuclein Expression Level
Unless otherwise specified, the fluorescence of the a-synuclein-GFP in each cell was normalized by dividing the a-synuclein-GFP
level measured at each time point by the mean mCherry level measured during the initial calibration phase. In the clearance analysis
(Figure 6), the fluorescence of the a-synuclein-GFP in each cell was normalized by dividing the a-synuclein-GFP level measured at
each time point by the mean a-synuclein-GFP level measured during the initial calibration phase of 5 min.
Single-Cell Analysis of Control Experiments
Single-cell data were collected from the time-lapse control experiments (Figure 3) according to the following procedure. The custom
segmentation and tracking algorithm (Method Details) processed the phase contrast images to extract single-cell traces. We
selected only single-cell traces longer than 500min. We then discarded the traces that did not reach a minimum expression level
during the time-course (16 normalized units forWT strain and 10 normalized units for A53Tmutant strain). We thus obtained 94 traces
for the WT strain and 128 for the A53T mutant strain. For each cell trace, we quantified the normalized fluorescence of a-synuclein
during the time-course. Next, we identified the cells that showed a-synuclein-GFP aggregates during the time-course (53 out 94 for
WT strain and 64 out of 128 for the A53T). To this end, we manually inspected single-cell movies to check if the cells formed aggre-
gates during the time-course. If so, we collected the aggregation time point tA defined as the time point at which the aggregates are
visible at the cell membrane. We obtained two datasets, one for the WT a-synuclein and one for the A53T mutant a-synuclein. The
aggregation threshold in each cell is defined as the a-synuclein-GFP normalized fluorescence level at the aggregation time-point tA.
Aggregation delay in each cell is defined as the time interval prior to the aggregation time-point tA during which the a-synuclein-GFP
fluorescence level was within 1 normalized unit from the aggregation threshold. Cell cycle duration in each cell is defined as the time
interval that occurs between two consecutive budding events. Cell cycle duration was quantified by inspecting manually the single-
cell movies.
Aggregation Threshold Estimation
Aggregation threshold for WT and A53T a-synuclein strains was precisely quantified by training a simple classifier on the single-cell
datasets. The aggregation classifier is mathematically defined by the map:
f : x˛R+/y˛
0
no aggregation
0
;
0
aggregation
0
which assigns a class label y to a normalized fluorescence level x. The map f is described as follows:
fðxÞ=
 0
no aggregation
0
; jx < l
0
aggregation
0
; jxRl
where l is the threshold level. Thus, the classifier is characterized by the parameter l. The performance of the classifier was evaluated
according to its accuracy ACC, defined as the rate of true predictions to total number of instances N:
ACC=
TP+TN
N
where TP and TN are respectively the true positives and the true negatives. Threshold levels for bothWT and A53T a-synuclein strains
were quantified by solving a maximization problem (Table S4). In particular, we searched the threshold level l which maximized the
prediction accuracy for WT and A53T single-cell datasets. The global optimization was performed using the MATLAB function ga of
theGlobal Optimization Toolbox. Classifier predictionwas validated by comparing its accuracy performancewith the one obtained by
a random classifier (Table S4). For each a-synuclein strain, random accuracy was computed using a bootstrapping procedure:
10,000 resampled datasets were generated, by randomly perturbing the class label assigned to each fluorescence level, and then
classified by the classifier. The random accuracy was quantified asmean accuracy of the distribution coming from the bootstrapping
procedure.
Single-Cell Analysis of Inclusions’ Clearance
Single-cell data were collected from the time-lapse clearance experiments (Figure 6) according to the following procedure. The
custom segmentation and tracking algorithm (Method Details) processed the phase contrast images to extract single-cell traces.Cell Reports 27, 916–927.e1–e5, April 16, 2019 e4
We visually identified the cells that showed a-synuclein-GFP inclusions during the initial calibration phase of 5min at the beginning of
the experiment when cells are still in the presence of galactose. The parameters time-to-first-bud, mean fluorescence, cell cycle
duration, and drop at division (Figure 6) were measured in each cell by using the following procedures. The time-to-first-bud was
computed by inspecting manually single-cell movies. The mean fluorescence was computed as the average a-synuclein-GFP fluo-
rescence from the beginning of the experiment until the time-to-first-bud. The cell cycle duration, as well as the budded phase, were
measured by inspecting manually single-cell movies. The drop at division was defined as the percentage decrease in fluorescence
during the budded phase of cell cycle in each cell.
Mathematical Model of Fluorescence Drop at Division
Cell cycle in yeast S. cerevisiae is divided in unbudded phase (G1) and budded phase (S-G2-M). Cell division occurs at the end of the
budded phase, when a new cell is born. To derive amathematical model of the fluorescence drop at division, we considered the linear
relationship between the size of the new-born cell (S
0
birth) and the size of the mother cell at the beginning of the budded phase ðSG1=SÞ
(Jonas et al., 2018):
S
0
birth = 0:61 SG1=S :
We assumed that mother cell mass was constant during the budded phase (Charvin et al., 2009):
SSG2M =SG1=S :
Thus, the total size of the cell and its bud at division ðSdivÞ was:
Sdiv =SSG2M +S
0
birth = 0:61 SG1=S +SG1=S = 1:61 SG1=S :
Hence, the percentage of mass lost by the mother cell at division ðDS%Þ was equal to:
DS% =
Sdiv  SSG2M
Sdiv
3 100=
0:61 SG1=S
1:61 SG1=S
3 100z38% :
We thus assumed a drop of 38% of fluorescence at each cell division.
Model Prediction Error of Fluorescence Drop at Division
Model prediction error of fluorescence at division was computed as percentage difference between the experimental fluorescence
measured at division and the value obtained in silico considering the mathematical model of fluorescence drop.
Correlation Analysis between Time-to-First-Bud and Inclusions’ Clearance Time
Correlation analysis in Figure S2B was performed using the function cor.test of the R environment that computes the Pearson’s
product moment correlation coefficient r. Moreover, the function also performed a test for assessing the statistical significance of
the correlation analysis ðp value < 2:23 1016Þ.
DATA AND SOFTWARE AVAILABILITY
All the data, the computational software, and the supplemental movies generated in this study are deposited at Zenodo (https://doi.
org/10.5281/zenodo.2546466).e5 Cell Reports 27, 916–927.e1–e5, April 16, 2019
